

Richter and Evestra share capital increase agreement

Budapest, Hungary – 22 July 2019 – Gedeon Richter Plc. („Richter”) today announced that it has subscribed to new shares of Evestra Inc. („Evestra”) amounting to USD 15 million. The transaction is part of a share capital increase initiated by Richter at the end of which Richter is expected to acquire 2,608,696 shares. The USD 1.5 million loan conceded to Evestra in 2017 will also be converted into equity stake resulting in an additional 333,333 shares. The combined number of shares to be owned by Richter will position the Company as the largest shareholder in Evestra with a 30.44% total ownership.

Richter and Evestra intend to deepen and to expand the scope of their collaboration in the field of Women’s Healthcare Research and Development in order to bring novel products to this niche market standing in the strategic focus of both companies.

Under the terms of the agreement, Richter reserves future option rights that entitles the Company to further increase its participation in the share capital of Evestra depending on future R&D milestones achieved.

“We are excited about the opportunity of taking the relationship between our companies to a new level. We look at Evestra as an outsourced research facility which is a perfect fit to Richter’s well established development and manufacturing capacities in the increasingly competitive Women’s Healthcare segment. A number of promising new projects including alternative drug delivery systems are under development,” stated Gábor Orbán, Chief Executive Officer of Richter.

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 3.2 billion (USD 3.6 billion) by the end of 2018, Richter's consolidated sales were approximately EUR 1.4 billion (USD 1.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

For further information:

Katalin Ördög, Investor Relations	+36 1 431 5680
Zsuzsa Beke, Public Relations	+36 1 431 4888